# Effect of Ticagrelor on Adenosine-Induced Coronary Flow Reserve in Patients With Microvascular Angina

Study · id `cardio:ct-nct02284048` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02284048](<https://clinicaltrials.gov/study/NCT02284048>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT02284048

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 140 participants.

## Technical summary

Registry record NCT02284048. Randomized; single masking; primary purpose treatment. Start 2014-11 (registry gives no type); primary completion 2016-11 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 140 participants (planned count; ClinicalTrials.gov record NCT02284048, source copy `cardio:ctgov-nct02284048-2014-11-06`, retrieved 2026-11-18)
- Start date: 2014-11 (registry gives no type) (ClinicalTrials.gov record NCT02284048, source copy `cardio:ctgov-nct02284048-2014-11-06`, retrieved 2026-11-18)
- Primary completion: 2016-11 (anticipated) (ClinicalTrials.gov record NCT02284048, source copy `cardio:ctgov-nct02284048-2014-11-06`, retrieved 2026-11-18)
- Completion: 2017-11 (anticipated) (ClinicalTrials.gov record NCT02284048, source copy `cardio:ctgov-nct02284048-2014-11-06`, retrieved 2026-11-18)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02284048-2014-11-06`, retrieved 2026-11-18)

## The registry's words

- Brief title: Effect of Ticagrelor on Adenosine-Induced Coronary Flow Reserve in Patients With Microvascular Angina
- Condition: Microvascular Angina
- Intervention (Drug): ticagrelor
- Lead sponsor: Second Xiangya Hospital of Central South University
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Angina pectoris (`cardio:angina-pectoris`)
- Registry condition terms include this condition: Microvascular and vasospastic angina (`cardio:microvascular-and-vasospastic-angina`)
- Registry intervention name matches this record: Ticagrelor (`cardio:ticagrelor`)
- Registry intervention is a member of this class by a sourced record link: P2Y12 inhibitors (drug class) (`cardio:p2y12-inhibitors`)
- Registry lists this organization as the lead sponsor: Second Xiangya Hospital of Central South University (`cardio:org-second-xiangya-hospital-of-central-south-university`)

## Provenance

Content hash: f5b6bc3ba0ba68cd8c9715e631756f1d70f5f9d470fa02cc9a0de635199172cd
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
